Diaz Allene M. 4
4 · IONIS PHARMACEUTICALS INC · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Diaz Allene M.
Director
Transactions
- Exercise/Conversion
Common Stock
2026-03-03$41.08/sh+10,321$423,987→ 28,689 total - Exercise/Conversion
Common Stock
2026-03-03$38.06/sh+12,000$456,720→ 40,689 total - Exercise/Conversion
Common Stock
2026-03-03$40.05/sh+18,000$720,900→ 58,689 total - Sale
Common Stock
[F1][F2]2026-03-03$79.11/sh−39,265$3,106,411→ 19,424 total - Sale
Common Stock
[F1][F3]2026-03-03$79.88/sh−14,608$1,166,814→ 4,816 total - Sale
Common Stock
[F1][F4]2026-03-03$80.80/sh−1,005$81,203→ 3,811 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−12,000→ 0 totalExercise: $38.06From: 2023-07-01Exp: 2032-06-30→ Common Stock (12,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−18,000→ 0 totalExercise: $40.05From: 2022-06-02Exp: 2031-06-30→ Common Stock (18,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−10,321→ 0 totalExercise: $41.08From: 2024-07-03Exp: 2033-07-02→ Common Stock (10,321 underlying)
Footnotes (4)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.565 to $79.565 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57to $80.55 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.61 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Allene M. Diaz|2026-03-05